Remicade Sales Aid Makes Misleading Efficacy Claims, FDA Tells J&J
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales aid improperly suggests the TNF-inhibitor can reverse or heal the disease process in patients with early rheumatoid arthritis, an FDA ad division “untitled” letter states. Agency also cites the promotion for omitting risk information. Centocor says the sales aid has not been used since October.
You may also be interested in...
Rheumatoid Arthritis Therapy “Healing” Evidence Lacks Precision, FDAer Says
Evidence of structural damage healing by rheumatoid arthritis agents has been incorrectly interpreted in some cases, FDA Medical Team Leader Siegel says. Radiographic signs of healing are often “statistical noise” or “an imprecision of readings.”
Rheumatoid Arthritis Therapy “Healing” Evidence Lacks Precision, FDAer Says
Evidence of structural damage healing by rheumatoid arthritis agents has been incorrectly interpreted in some cases, FDA Medical Team Leader Siegel says. Radiographic signs of healing are often “statistical noise” or “an imprecision of readings.”
Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter
Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.